Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 8, p. 4415, doi. 10.1111/dom.16478
- By:
- Publication type:
- Article